139 related articles for article (PubMed ID: 35837160)
1. The bevacizumab plus oxaliplatin-based chemotherapy regimen is more suitable for metastatic colorectal cancer patients with a history of schistosomiasis: a clinical retrospective analysis.
Zhou LN; Feng CX; Zhang Y; Li P; Tang M; Chen MB; Jin J
J Gastrointest Oncol; 2022 Jun; 13(3):1086-1096. PubMed ID: 35837160
[TBL] [Abstract][Full Text] [Related]
2. The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia.
Overman MJ; Ferrarotto R; Raghav K; George B; Qiao W; Machado KK; Saltz LB; Mazard T; Vauthey JN; Hoff PM; Hobbs B; Loyer EM; Kopetz S
J Natl Cancer Inst; 2018 Aug; 110(8):888-894. PubMed ID: 29346573
[TBL] [Abstract][Full Text] [Related]
3. aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.
Fujita Y; Taguri M; Yamazaki K; Tsurutani J; Sakai K; Tsushima T; Nagase M; Tamagawa H; Ueda S; Tamura T; Tsuji Y; Murata K; Taira K; Denda T; Moriwaki T; Funai S; Nakajima TE; Muro K; Tsuji A; Yoshida M; Suyama K; Kurimoto T; Sugimoto N; Baba E; Seki N; Sato M; Shimura T; Boku N; Hyodo I; Yamanaka T; Nishio K
Oncologist; 2019 Mar; 24(3):327-337. PubMed ID: 30425180
[TBL] [Abstract][Full Text] [Related]
4. Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis.
Golfinopoulos V; Salanti G; Pavlidis N; Ioannidis JP
Lancet Oncol; 2007 Oct; 8(10):898-911. PubMed ID: 17888735
[TBL] [Abstract][Full Text] [Related]
5. Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study.
Di Bartolomeo M; Ciarlo A; Bertolini A; Barni S; Verusio C; Aitini E; Pietrantonio F; Iacovelli R; Dotti KF; Maggi C; Perrone F; Bajetta E
Eur J Cancer; 2015 Mar; 51(4):473-481. PubMed ID: 25637137
[TBL] [Abstract][Full Text] [Related]
6. FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study.
Iwamoto S; Takahashi T; Tamagawa H; Nakamura M; Munemoto Y; Kato T; Hata T; Denda T; Morita Y; Inukai M; Kunieda K; Nagata N; Kurachi K; Ina K; Ooshiro M; Shimoyama T; Baba H; Oba K; Sakamoto J; Mishima H
Ann Oncol; 2015 Jul; 26(7):1427-33. PubMed ID: 25908603
[TBL] [Abstract][Full Text] [Related]
7. Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen.
Tanioka H; Shimada K; Tsuji A; Kochi M; Kim HM; Takahashi T; Denda T; Takagane A; Watanabe T; Kotaka M; Nakamura M; Sunakawa YU; Takeuchi M; Ichikawa W; Fujii M
Anticancer Res; 2022 May; 42(5):2675-2681. PubMed ID: 35489740
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study).
Moriwaki T; Bando H; Takashima A; Yamazaki K; Esaki T; Yamashita K; Fukunaga M; Miyake Y; Katsumata K; Kato S; Satoh T; Ozeki M; Baba E; Yoshida S; Boku N; Hyodo I
Med Oncol; 2012 Dec; 29(4):2842-8. PubMed ID: 22209842
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of S-1-based sequential combination chemotherapy including oxaliplatin plus bevacizumab and irinotecan with or without cetuximab for metastatic colorectal cancer: the SOBIC trial.
Nakamoto Y; Noda M; Mikami R; Tokunaga Y; Okumoto T; Kawamura T; Fujiwara H; Doi S; Tomita N
Int J Clin Oncol; 2020 Jul; 25(7):1285-1290. PubMed ID: 32200481
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer.
Bazarbashi S; Aljubran A; Alzahrani A; Mohieldin A; Soudy H; Shoukri M
Cancer Med; 2015 Oct; 4(10):1505-13. PubMed ID: 26207614
[TBL] [Abstract][Full Text] [Related]
11. S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102).
Miyamoto Y; Tsuji A; Tanioka H; Maekawa S; Kawanaka H; Kitazono M; Oki E; Emi Y; Murakami H; Ogata Y; Saeki H; Shimokawa M; Natsugoe S; Akagi Y; Baba H; Maehara Y
Int J Clin Oncol; 2016 Aug; 21(4):705-712. PubMed ID: 26746689
[TBL] [Abstract][Full Text] [Related]
12. S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial.
Yamada Y; Denda T; Gamoh M; Iwanaga I; Yuki S; Shimodaira H; Nakamura M; Yamaguchi T; Ohori H; Kobayashi K; Tsuda M; Kobayashi Y; Miyamoto Y; Kotake M; Shimada K; Sato A; Morita S; Takahashi S; Komatsu Y; Ishioka C
Ann Oncol; 2018 Mar; 29(3):624-631. PubMed ID: 29293874
[TBL] [Abstract][Full Text] [Related]
13. [KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer].
Cabart M; Frénel JS; Campion L; Ramée JF; Dupuis O; Senellart H; Hiret S; Douillard JY; Bennouna J
Bull Cancer; 2016 Jun; 103(6):541-51. PubMed ID: 27155924
[TBL] [Abstract][Full Text] [Related]
14. Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal Cancer.
van Nassau SC; Bond MJ; Scheerman I; van Breeschoten J; Kessels R; Valkenburg-van Iersel LB; Verheul HM; Buffart TE; Mekenkamp LJ; Lemmens VE; Koopman M; Bol GM;
JAMA Netw Open; 2021 Sep; 4(9):e2124766. PubMed ID: 34505885
[TBL] [Abstract][Full Text] [Related]
15. The addition of bevacizumab to fluoropyrimidine, irinotecan and oxaliplatin-based therapy improves survival for patients with metastatic colorectal cancer (CRC): combined analysis of efficacy.
Popov I; Milicević M; Radosević-Jelić Lj
Acta Chir Iugosl; 2008; 55(4):11-6. PubMed ID: 19245134
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab plus irinotecan-based therapy in metastatic colorectal cancer patients previously treated with oxaliplatin-based regimens.
Yildiz R; Buyukberber S; Uner A; Yamac D; Coskun U; Kaya AO; Ozturk B; Yaman E; Benekli M
Cancer Invest; 2010 Jan; 28(1):33-7. PubMed ID: 19995229
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients.
Catalano V; Bergamo F; Cremolini C; Vincenzi B; Negri F; Giordani P; Alessandroni P; Intini R; Stragliotto S; Rossini D; Borelli B; Santini D; Sarti D; Rocchi MBL; Lonardi S; Falcone A; Zagonel V; Mattioli R; Graziano F
J Cancer Res Clin Oncol; 2020 Feb; 146(2):493-501. PubMed ID: 31691872
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer.
Yang Q; Yin C; Liao F; Huang Y; He W; Jiang C; Guo G; Zhang B; Xia L
Onco Targets Ther; 2015; 8():2407-13. PubMed ID: 26366095
[TBL] [Abstract][Full Text] [Related]
19. Primary tumor location and survival in colorectal cancer: A retrospective cohort study.
Aggarwal H; Sheffield KM; Li L; Lenis D; Sorg R; Barzi A; Miksad R
World J Gastrointest Oncol; 2020 Apr; 12(4):405-423. PubMed ID: 32368319
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group.
Schmiegel W; Reinacher-Schick A; Arnold D; Kubicka S; Freier W; Dietrich G; Geißler M; Hegewisch-Becker S; Tannapfel A; Pohl M; Hinke A; Schmoll HJ; Graeven U
Ann Oncol; 2013 Jun; 24(6):1580-7. PubMed ID: 23463625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]